Lopicure-TG Tablet is a combination lipid-lowering agent containing Atorvastatin 10mg and Fenofibrate 160mg, indicated for the management of mixed dyslipidemia and hypertriglyceridemia. Atorvastatin, a selective HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and total cholesterol by inhibiting the rate-limiting step in cholesterol biosynthesis. Fenofibrate, a fibric acid derivative, primarily lowers triglyceride levels and increases high-density lipoprotein cholesterol (HDL-C) by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. The combined action of these agents provides a comprehensive approach to lipid abnormalities, particularly in patients who do not achieve target lipid levels with monotherapy. Lopicure-TG is indicated for patients with mixed dyslipidemia characterized by elevated LDL-C and triglycerides, and for those at high risk of cardiovascular events due to persistent hypertriglyceridemia. It should be used as an adjunct to diet and lifestyle modifications. Caution is advised in patients with hepatic or renal impairment, and regular monitoring of liver function tests and creatine kinase levels is recommended to minimize the risk of adverse effects such as myopathy or hepatotoxicity. Lopicure-TG should be prescribed under medical supervision with appropriate patient education on adherence and potential side effects.